Susquehanna Fundamental Investments LLC Raises Stock Position in BWX Technologies, Inc. $BWXT

Susquehanna Fundamental Investments LLC boosted its position in BWX Technologies, Inc. (NYSE:BWXT) by 200.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,388 shares of the technology company’s stock after purchasing an additional 45,605 shares during the quarter. Susquehanna Fundamental Investments LLC owned about 0.07% of BWX Technologies worth $13,312,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. M.D. Sass LLC purchased a new stake in shares of BWX Technologies in the 2nd quarter valued at about $2,619,000. Ranger Investment Management L.P. purchased a new position in shares of BWX Technologies during the first quarter worth about $11,991,000. MGO One Seven LLC increased its position in shares of BWX Technologies by 354.7% in the fourth quarter. MGO One Seven LLC now owns 17,695 shares of the technology company’s stock worth $3,058,000 after purchasing an additional 13,803 shares during the last quarter. Intech Investment Management LLC increased its position in shares of BWX Technologies by 22.7% in the fourth quarter. Intech Investment Management LLC now owns 32,668 shares of the technology company’s stock worth $5,646,000 after purchasing an additional 6,053 shares during the last quarter. Finally, Mizuho Markets Americas LLC purchased a new stake in BWX Technologies in the fourth quarter valued at approximately $36,097,000. 94.39% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on BWXT shares. Truist Financial dropped their target price on shares of BWX Technologies from $212.00 to $202.00 and set a “hold” rating for the company in a research report on Friday, August 14th. Seaport Research Partners upgraded shares of BWX Technologies from a “neutral” rating to a “buy” rating and set a $245.00 price objective on the stock in a research report on Monday, June 22nd. JPMorgan Chase & Co. began coverage on shares of BWX Technologies in a report on Monday, July 27th. They set an “overweight” rating and a $230.00 price objective for the company. Deutsche Bank Aktiengesellschaft raised BWX Technologies from a “hold” rating to a “buy” rating and increased their target price for the company from $205.00 to $255.00 in a research note on Friday, May 15th. Finally, Wells Fargo & Company upgraded BWX Technologies from an “underweight” rating to an “equal weight” rating and lowered their price target for the company from $200.00 to $170.00 in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $224.20.

Insider Buying and Selling

In other BWX Technologies news, CEO Rex D. Geveden sold 10,000 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $172.50, for a total transaction of $1,725,000.00. Following the completion of the sale, the chief executive officer owned 192,491 shares of the company’s stock, valued at $33,204,697.50. This represents a 4.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.60% of the stock is owned by corporate insiders.

BWX Technologies Trading Up 0.2%

Shares of BWXT stock opened at $153.12 on Monday. The business has a 50-day moving average of $175.83 and a 200 day moving average of $195.75. The company has a debt-to-equity ratio of 1.51, a current ratio of 2.40 and a quick ratio of 2.33. BWX Technologies, Inc. has a 1-year low of $147.74 and a 1-year high of $241.82. The stock has a market capitalization of $14.03 billion, a PE ratio of 39.67, a P/E/G ratio of 2.39 and a beta of 0.76.

BWX Technologies (NYSE:BWXT) last announced its quarterly earnings results on Monday, August 3rd. The technology company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $1.04 by $0.03. BWX Technologies had a return on equity of 30.83% and a net margin of 10.11%.The business had revenue of $901.62 million for the quarter, compared to analysts’ expectations of $902.41 million. During the same period in the previous year, the firm earned $1.02 EPS. The business’s quarterly revenue was up 18.0% on a year-over-year basis. BWX Technologies has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, sell-side analysts anticipate that BWX Technologies, Inc. will post 4.75 earnings per share for the current year.

BWX Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 4th. Investors of record on Tuesday, August 18th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Tuesday, August 18th. BWX Technologies’s dividend payout ratio is currently 27.98%.

BWX Technologies Company Profile

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non?defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.